Literature DB >> 7926915

Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemochromatosis.

Y M Deugnier1, A F Rabot, D Guyader, R Moirand, B Turlin, E Boucher, P Lebert, P Brissot.   

Abstract

CA 19.9 antigen is mainly secreted by biliary and pancreatic duct cells. Its metabolism could be modified in genetic haemochromatosis by iron accumulation within these cells. Therefore, CA 19.9 was assayed in the serum samples of 84 patients with genetic haemochromatosis before and after iron depletion and immunolocalised in the liver of 24 untreated genetic haemochromatosis cases. The study showed that serum CA 19.9 (N < 37 IU/l) was increased (SD) before treatment (41.2 (34)) when compared with after the venesection period (16 (12)), and correlated, before treatment, with the amount of iron excess, transaminases, fibrosis, and biliary iron deposits. Hepatic CA 19.9 was located within the cytoplasm of bile duct and cholangiolar cells. In conclusion, this study shows that a mild, reversible, and non-specific increase in serum CA 19.9 is common in genetic haemochromatosis patients and shows that this increase is related to iron excess, directly or through associated liver damage. The unexplained finding of a mild increase in serum CA 19.9 should lead, in a patient with no diagnosis, to the search for liver iron overload, and, in a patient with untreated genetic haemochromatosis, not to further diagnostic procedures unless this finding persists after completion of the venesection treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7926915      PMCID: PMC1375064          DOI: 10.1136/gut.35.8.1107

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

Review 1.  Glycosyltransferases. Structure, localization, and control of cell type-specific glycosylation.

Authors:  J C Paulson; K J Colley
Journal:  J Biol Chem       Date:  1989-10-25       Impact factor: 5.157

2.  Serum desialylated glycoproteins in patients with hepatobiliary dysfunction.

Authors:  J S Marshall; S Williams; P Jones; G W Hepner
Journal:  J Lab Clin Med       Date:  1978-07

3.  Expression of hemochromatosis in homozygous subjects. Implications for early diagnosis and prevention.

Authors:  L W Powell; K M Summers; P G Board; E Axelsen; S Webb; J W Halliday
Journal:  Gastroenterology       Date:  1990-06       Impact factor: 22.682

4.  Measurement of liver-iron concentration in needle-biopsy specimens.

Authors:  M Barry; S Sherlock
Journal:  Lancet       Date:  1971-01-16       Impact factor: 79.321

Review 5.  The role of sialic acid in determining the life-span of circulating cells and glycoproteins.

Authors:  V Bocci
Journal:  Experientia       Date:  1976-02-15

6.  Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.

Authors:  F Safi; R Roscher; H G Beger
Journal:  Hepatogastroenterology       Date:  1989-12

7.  Glycosyltransferases in human blood. II. Study of serum galactosyltransferase and N-acetylgalactosaminyltransferase in patients with liver diseases.

Authors:  Y S Kim; J Perdomo; J S Whitehead; K J Curtis
Journal:  J Clin Invest       Date:  1972-08       Impact factor: 14.808

8.  Measurement of circulating desialylated glycoproteins and correlation with hepatocellular damage.

Authors:  J S Marshall; A M Green; J Pensky; S Williams; A Zinn; D M Carlson
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

9.  Elevated serum levels of tumor marker CA19-9 in acute cholangitis.

Authors:  M B Albert; W M Steinberg; J P Henry
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

10.  Clinical and laboratory evaluation of CA 19-9 in cirrhotic patients.

Authors:  J Collazos
Journal:  Eur J Med       Date:  1992 Jul-Aug
View more
  1 in total

1.  Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution.

Authors:  Joo Kyung Park; Woo Hyun Paik; Ji Kon Ryu; Yong-Tae Kim; Youn Joo Kim; Jaihwan Kim; Byeong Jun Song; Jin Myung Park; Yong Bum Yoon
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.